AzTrials
AzTrials

Abdominal ImagingNCT05261633

Diffusion MRI of the Abdomen

An observational study of Abdominal Imaging, run by University of Wisconsin, Madison at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this research is to see if a new magnetic resonance imaging (MRI) method will be able to improve the images taken of the abdomen. This new method includes some changes to help avoid movements that may disrupt the images like breathing, heartbeats and other involuntary motion that occurs in the abdomen. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Abdominal Imaging
What is being tested?
Diffusion Weighted Magnetic Resonance Imaging
How many people
17 participants
Where
1 siteUnited States
Study dates
22 Nov 2023to 30 Jun 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Healthy volunteers and people with known liver metastases that are 18 years or older.

Who may be able to join

  • 18 years of age or older
  • 18 years of age or older
  • Patients with at least one of the following:
  • Radiologically visible solid tumor liver metastasis, with at least one metastatic liver lesion must be a minimum of 8 mm in longest diameter
  • Patients presenting for liver lesion biopsy

Who cannot join

  • Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)
  • Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)
  • Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)
  • Patients with known contraindication to GBCA such as severe kidney disease or previously documented GFR < 30 ml/min/1.73 m2
  • Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:
  • The subject has their own prescription for the medication.
Show all 11Show fewer
  • The informed consent process is conducted prior to the self-administration of this medication
  • They come to the research visit with a driver
  • Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)
  • Stent in bile ducts
  • Partial hepatectomy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Wisconsin School of Medicine and Public Health

    Madison, Wisconsin, 53792

Other trials in United States

About this study

Official title: Diffusion Magnetic Resonance Imaging (MRI) of the Abdomen

The purpose of this research is to see if a new magnetic resonance imaging (MRI) method will be able to improve the images taken of the abdomen. This new method includes some changes to help avoid movements that may disrupt the images like breathing, heartbeats and other involuntary motion that occurs in the abdomen. This study will these methods in healthy volunteers and validate them in patients with known liver metastases in a single contrast-enhanced MRI visit.

Read the detailed description

This study will develop and validate novel DW-MRI methods with unprecedented robustness to motion, favorable image quality, and quantitative precision for abdominal imaging. Upon successful completion, these methods will have broad applications, including the assessment of cancer, fibrosis and other disease processes in various abdominal organs such as the liver, pancreas, kidneys, bowel and beyond.

The primary objective is to demonstrate precise quantitative diffusion parameter mapping that is achieved by the novel, motion-robust, low-distortion DW-MRI methods in a representative and clinically relevant application, for the assessment of liver metastatic disease. Specifically, the investigators will:

  1. Compare the repeatability of DW-MRI methods by calculating the squared difference between each pair of repeated ADC measurements in lesions and healthy tissue, and will model this value including the DW-MRI method as a covariate using Generalized Estimating Equations (GEE).

Secondary objectives include optimization of the methods in healthy volunteers, assessment of image quality and distortions, as well gathering preliminary data for assessment of sensitivity and specificity for detection of lesions:

  1. Optimization in healthy volunteers
  2. (Aim 1) Optimized bh, M1 and M2 parameters by minimization of the mean squared error and bias of ADC quantification across the liver
  3. (Aim 2) Optimized motion-corrected averaging via image quality assessment by three radiologists using a Likert scale.
  4. SNR (signal-to-noise ratio) will be evaluated for each DW-MRI dataset, using an expectation-maximization method, accounting for parallel imaging, spatially varying noise, and magnitude operation.
  5. To assess image distortions in DW-MRI, the cross-correlation coefficient (CCC) will be used to assess alignment between each of the DW-MRI datasets and the reference T2-weighted acquisition.
  6. Each DW-MRI reconstruction will be evaluated by three radiologists using a Likert scale between 0 (worst/non-diagnostic) and 4 (best) for several criteria: motion artifacts, spatial resolution, distortions, apparent SNR, and overall image quality. The post-contrast images will serve as a guide to assess for artifacts by demonstrating the liver and the lesions.
  7. Per-lesion sensitivity, specificity, and accuracy will be assessed for each DW-MRI method. McNemar's test will be used to compare the sensitivity and specificity between methods.
  8. Intra-reader variability will be assessed by each reader will repeating ADC measurements after two months.
  9. Inter-reader variability will be assessed in ADC measurements by comparing matching lesions, based on the recorded lesion location across readers.

Specific Aims Aim 1: Optimize a reliable, motion-robust DW-MRI of the abdomen in healthy volunteers.

Aim 2: Optimize, in healthy volunteers, a high-resolution, low-distortion, motion-robust DW-MRI of the abdomen through the synergistic combination of motion-robust DW-MRI with state-of-the-art low-distortion techniques.

Aim 3: Demonstrate excellent image quality and precise quantitative diffusion parameter mapping using the novel DW-MRI methods in a representative and clinically relevant application for the assessment of liver metastases, by evaluating in patients:

3a. Quantitative and subjective image quality metrics. 3b. Precision (test-retest repeatability) of ADC measurements in the liver (including healthy parenchyma and lesions) by novel vs. standard DW-MRI methods.

Being tested
Diffusion Weighted Magnetic Resonance Imaging

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Diffusion Weighted Magnetic Resonance ImagingDevice

    Also called DW-MRI

    Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.

Study groups in NCT05261633
Study groupRoleWhat they receive
Healthy VolunteersNot described
Receives: Device: Diffusion Weighted Magnetic Resonance Imaging
Known Liver MetastasesNot described
Receives: Device: Diffusion Weighted Magnetic Resonance Imaging

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Squared difference between each pair of repeated ADC measurements

    Compare the repeatability of DW-MRI methods by calculating the squared difference between each pair of repeated apparent diffusion coefficient (ADC) measurements in lesions and healthy tissue, and will model this value including the DW-MRI method as a covariate using Generalized Estimating Equations (GEE).

    Measured: up to 1.5 hours

Secondary outcomes (10)
  1. Mean Squared Error of ADC in images from Healthy Volunteers

    Optimized bh, M1 and M2 parameters in healthy volunteers by minimization of the mean squared error and bias of ADC quantification across the liver.

    Measured: up to 1.5 hours

  2. Image Quality Score in images from Healthy Volunteers

    Optimized motion-corrected averaging in healthy volunteers via image quality assessment by three radiologists using a Likert scale, ranging between 0 (worst/non-diagnostic) and 4 (best).

    Measured: up to 1.5 hours

  3. Signal-to-Noise Ratio (SNR)

    SNR will be evaluated for each DW-MRI dataset, using an expectation-maximization method, accounting for parallel imaging, spatially varying noise, and magnitude operation

    Measured: up to 1.5 hours

  4. Cross-correlation coefficient (CCC) of images

    To assess image distortions in DW-MRI, the cross-correlation coefficient (CCC) will be used to assess alignment between each of the DW-MRI datasets and the reference T2-weighted acquisition.

    Measured: up to 1.5 hours

  5. Overall Image Quality Score

    Each DW-MRI reconstruction will be evaluated by three radiologists using a Likert scale between 0 (worst/non-diagnostic) and 4 (best) for several criteria: motion artifacts, spatial resolution, distortions, apparent SNR, and overall image quality. The post-contrast images will serve as a guide to assess for artifacts by demonstrating the liver and the lesions.

    Measured: up to 1.5 hours

  6. Sensitivity: Number of True Positive Assessments divided by Number of All Positive Assessments

    Per-lesion sensitivity will be assessed for each DW-MRI method. McNemar's test will be used to compare the sensitivity and specificity between methods.

    Measured: up to 1.5 hours

  7. Specificity: Number of True Negative Assessments divided by Number of All Negative Assessments

    Per-lesion specificity will be assessed for each DW-MRI method. McNemar's test will be used to compare the sensitivity and specificity between methods.

    Measured: up to 1.5 hours

  8. Accuracy: Number of Correct Assessments divided by Number of All Assessments

    Per-lesion accuracy will be assessed for each DW-MRI method. McNemar's test will be used to compare the sensitivity and specificity between methods.

    Measured: up to 1.5 hours

  9. Repeat ADC Measurements to Assess Intra-Reader Variability

    Intra-reader variability will be assessed by each reader with repeating ADC measurements after two months

    Measured: up to 1.5 hours

  10. ACD Measures For Each Reader to assess Inter-Reader Variability

    Inter-reader variability will be assessed in ADC measurements by comparing matching lesions, based on the recorded lesion location across readers.

    Measured: up to 1.5 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2022
  2. Study start22 Nov 2023
  3. Primary completion30 Jun 2026
  4. Study completion30 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
17 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05261633
Sponsor's protocol ID
2021-1289
Other IDs
Protocol Version 10/17/2025, A539300, 1R01EB030497-01
Status last verified
Jun 2026
First submitted
3 Feb 2022
Last updated
2 Jul 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Abdominal Imaging, run by University of Wisconsin, Madison at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Squared difference between each pair of repeated ADC measurements (time frame: up to 1.5 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in